The global biopharmaceutical contract manufacturing market is on a significant growth trajectory, with its value expected to reach USD 10.7 billion in 2024. According to recent projections, the market is set to expand at a compound annual growth rate (CAGR) of 8.8%, culminating in a valuation of USD 25.1 billion by 2034.
This robust growth is fueled by the increasing complexity of biologics, which are intricate molecules requiring specialized expertise for their production. Pharmaceutical companies, especially small and mid-sized biopharmaceutical firms, are increasingly outsourcing their manufacturing processes to contract manufacturing organizations (CMOs) due to the lack of in-house resources and expertise.
As the biopharmaceutical market expands globally, the demand for efficient manufacturing processes is intensifying. A key trend driving this market growth is the rising adoption of cell and gene therapies. These advanced therapies necessitate specialized manufacturing facilities and technical know-how, which CMOs are uniquely positioned to provide. This is leading to a rapid increase in the demand for their services.
However, the market is not without its challenges. The risk of intellectual property theft remains a significant concern for industry players. CMOs often work with multiple clients, raising the possibility of confidential information being inadvertently shared or stolen. This could lead to legal disputes and damage to the contract manufacturer’s reputation, potentially hampering market growth during the forecast period.
To maintain a competitive edge, contract manufacturers must continuously adapt to emerging technologies and procedures in the sector. Staying at the forefront of industry advancements will be crucial for CMOs as they navigate the evolving landscape of biopharmaceutical manufacturing.
As the industry continues to grow, stakeholders must address these challenges proactively to ensure sustainable progress and the continued delivery of high-quality biopharmaceutical products to the global market.
“The increased usage of biologics in a variety of therapeutic areas, a growing need for customized treatment, and the emergence of new manufacturing technologies that allow for more efficient and cost-effective biopharmaceutical production drive the market’s progress,” says an analyst at FMI.
Key Takeaways from the Biopharmaceutical Contract Manufacturing Market:
- The global biopharmaceutical contract manufacturing market is estimated to register a CAGR of 8.8% through 2034.
- The market is expected to reach a valuation of USD 25.1 billion by 2034.
- The mammalian-based segment is anticipated to dominate the market, accounting for 73.0% of the market share in 2024.
- With a 51.0% market share, the monoclonal antibodies segment is estimated to dominate the market in 2024.
Explore the Full Market Scope: Find the Complete Biopharmaceutical Contract Manufacturing Market Report Here
Competitive Landscape:
The biopharmaceutical contract manufacturing industry is getting more competitive as the demand for biologics and biosimilars rises. Companies have a solid reputation for offering high-quality contract manufacturing services to the biopharmaceutical industry. However, some smaller market participants are gaining traction and competing with the larger corporations by providing specialized services and innovative technologies.
Some prominent companies in the market include Catalent Inc., Lonza Group Ag, Patheon N.V. (Thermo Fisher Scientific Inc.), Abzena Plc., Sandoz International GmbH (Novartis AG), Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings), Baxter Pharmaceutical Solutions LLC (Baxter Inc.), AbbVie Contract Manufacturing (AbbVie Inc.), Samsung Biologics Co. Ltd., ProBioGen AG, Pfizer Centre Source Ltd.
Key Market Segments:
By Platform Type:
- Mammalian Based
- Microbial Based
By Product Type:
- Monoclonal Antibodies
- Recombinant Protein
- Vaccine
- Insulin
- Growth factor
- Interferons
- Others
By Application Type:
- Clinical
- Commercial
By Therapeutic Area Type:
- Autoimmune Diseases
- Oncology
- Metabolic Diseases
- Ophthalmology
- Cardiovascular Diseases
- Infectious Diseases
- Neurology
- Respiratory Disorders
- Others
By Region:
- North America
- Latin America
- East Asia
- South Asia
- Europe
- Oceania
- MEA
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube